Kidney condition in patients with spondyloarthritis receiving genetically engineered biologic drugs
- Авторлар: Dorogoykina K.D1, Sedov D.S1, Gamayunova K.A1, Rebrov A.P1
-
Мекемелер:
- Saratov State Medical University named after V.l. Razumovsky
- Шығарылым: Том 12, № 2 (2020)
- Беттер: 21-25
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/273278
- DOI: https://doi.org/10.18565/nephrology.2020.2.21-25
- ID: 273278
Дәйексөз келтіру
Аннотация
Толық мәтін
Авторлар туралы
K. Dorogoykina
Saratov State Medical University named after V.l. Razumovsky
Email: dorogoykinakd@mail.ru
Postgraduate Student at the Department of Hospital Therapy, Faculty of Medicine Saratov, Russia
D. Sedov
Saratov State Medical University named after V.l. Razumovsky
Email: 77sedov77@mail.ru
Postgraduate Student at the Department of Hospital Therapy, Faculty of Medicine Saratov, Russia
K. Gamayunova
Saratov State Medical University named after V.l. Razumovsky
Email: k.a.gamayunova@mail.ru
Postgraduate Student at the Department of Hospital Therapy, Faculty of Medicine Saratov, Russia
A. Rebrov
Saratov State Medical University named after V.l. Razumovsky
Email: andreyrebrov@yandex.ru
Doctor of Medical Sciences, Professor, Head of the Department of Hospital Therapy, Faculty of Medicine Saratov, Russia
Әдебиет тізімі
- Couderc M, Pereira B., Molto A., et al. The Prevalence of Renal Impairment in Patients with Spondyloarthritis: Results from the International ASAS-COMOSPA Study. J. Rheumatol. 2018;45(6):795-801. doi: 10.3899/jrheum.170133.
- Моминова Г.Н., Кулымбетова Б.А., Султанбекова А.О. и др. Опыт применения генно-инженерных препаратов у пациента с анкилозирующим спон-дилоартритом, осложненным АА-амилоидозом почек. Вестник Казахского Национального медицинского университета. 2018;2:501-504.
- Муравьев Ю.В., Муравьева Л.А. Проблема лабораторного мониторинга при терапии базисными противовоспалительными и генно-инженерными биологическими препаратами у больных ревматоидным артритом. Современная ревматология. 2018; 12(3): 120-123
- Ota M., Iwai H., Imai K., et al. Acute Tubulointerstitial Nephritis Associated with Infliximab in a Patient with Crohn’s Disease. Intern Med. 2016;55:1367-1370. doi: 10.2169/internalmedicine.55.5834.
- Costa M.F., Said N.R., Zimmermann B. Drug-induced lupus due to antitumor necrosis factor a agents. Semin. Arthr. Rheum. 2008;37:381-387. doi: 10.1016/j.semarthrit.2007.08.003.
- Bhagat Singh A.K., Jeyaruban A.S., Wilson G.J., et al. Adalimumab-induced IgA nephropathy. BMJ Case Reports CP. 2019;12:e226442. Doi: 10.1136/ bcr-2018-226442.
- Yarkan Tugsal H., Zengin B., Kenar G., et al. Infliximab-associated focal segmental glomerulosclerosis in a patient with ankylosing spondylitis. Rheumatol. Int. 2019;39(3):561-567. doi: 10.1007/s00296-019-04241-8.
- Годзенко А.А. Поражение почек при серонегативных спондилоартритах. Трудный пациент. 2006;4(7):46-8.
- Barbouch S., Hajji M., Jaziri F., et al. Renal amyloidosis in ankylosing spondylitis: A monocentric study and review of literature. Saudi J. Kidney Dis. Transpl. 2018;29:386-391. doi: 10.4103/1319-2442.229291.
- Verschueren P., Lensen F., Lerut E. Benefit of anti-TNF-a treatmentfor nephritic syndrome in patient with juvenile inflammatory bowel disease associated spondyloarthropathy complicated with amyloidosis and glomerulonephritis. Ann. Rhem. Dis. 2003;62:368-369.
- Donmez S., Pamuk O.N., Pamuk G.E., et al. Secondary amyloidosis in ankylosing spondylitis. Rheumatol. Int. 2013;33(7):1725-1729. Doi: 10.1007/ s00296-012-2646-3.
- Lee Y.H., Kim E.Y., Jeong D.W. Complete Remission of Nephrotic Syndrome Without Resolution of Amyloid Deposit After Anti-Tumor Necrosis Factor a Therapy in a Patient With Ankylosing Spondylitis. J. Clin. Rheumatol. 2016;22(2):86-88. doi: 10.1097/RHU.0000000000000356.